首页 | 本学科首页   官方微博 | 高级检索  
检索        

金龙胶囊减少肝癌患者TACE术后不良反应的临床分析
引用本文:黄伍奎,樊喜文,杨树法,由丽娜,帕哈尔丁白克热,刘墨,顾朋,王萍菊.金龙胶囊减少肝癌患者TACE术后不良反应的临床分析[J].中国肿瘤临床,2013,40(3):157-160.
作者姓名:黄伍奎  樊喜文  杨树法  由丽娜  帕哈尔丁白克热  刘墨  顾朋  王萍菊
作者单位:①.新疆医科大学附属肿瘤医院介入室(乌鲁木齐市 830011)
摘    要:  目的  探讨金龙胶囊减少原发性肝癌患者行肝动脉插管灌注化疗栓塞术后不良反应的作用。  方法  82例原发性肝癌患者按随机原则分为对照组和试验组。在肝动脉插管灌注化疗栓塞术后第1日, 试验组患者开始口服金龙胶囊, 对照组不服用, 其余治疗措施相同。  结果  试验组患者红细胞和血小板下降的例数较少(P < 0.05), 两组总胆红素差异无统计学意义(P > 0.05), 谷丙转氨酶、白蛋白、钾、钠与对照组比较差异有统计学意义(P < 0.05), 试验组患者术后5 d的食欲、精神、睡眠、疲乏评分情况优于对照组, 腹痛、腹胀持续时间较短(P < 0.05)。  结论  金龙胶囊能减少TACE患者术后部分不良反应的发生, 缩短不良反应持续的时间, 能提高TACE患者术后近期生活质量, 减少TACE对患者机体的损伤。 

关 键 词:金龙胶囊    肝癌TACE    不良反应
收稿时间:2012-09-17

Clinical observation of decreasing adverse reaction for Jinlong capsule after transcatheter arterial chemoembolization to patients with heptocellular carcinoma
Wukui HUANG,Xiwen FAN,Shufa YANG,Lina YOU,Baikere PAHAERDING,Mo LIU,Peng GU,Pingju WANG.Clinical observation of decreasing adverse reaction for Jinlong capsule after transcatheter arterial chemoembolization to patients with heptocellular carcinoma[J].Chinese Journal of Clinical Oncology,2013,40(3):157-160.
Authors:Wukui HUANG  Xiwen FAN  Shufa YANG  Lina YOU  Baikere PAHAERDING  Mo LIU  Peng GU  Pingju WANG
Institution:①.Department of Intervention Radiology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urmqi 830011, China②.Department of Traditional Chinese Medicinel, The Fifth Affiliated Hospital of Xinjiang Medical University, Urmqi 830011, China
Abstract:  Objective  This study aims to discuss the effect of Jinlong capsule on decreasing adverse reaction after transcatheter arterial chemoembolization(TACE)for patients with heptocellular carcinoma.  Methods  We divided 82 patients with heptocellular carcinoma into the contrast group and experiment group using random principle.On the first day after TACE, the experiment group started to take Jinlong capsule orally, whereas the contrast group did not; other treatment methods were the same.  Results  The decreased cases of the red blood cell and thrombocyte in the experiment group were lower than those in the contrast group(P < 0.05);the variance of the total bilirubin had no statistical significance between the two groups(P > 0.05), whereas statistical significance was observed on the variance of Alanine transaminase, albumin, potassium, and sodium in the blood between two groups(P < 0.05).Five days after TACE, the score of appetite, energy, sleep, and fatigue for the experiment group were superior to the contrast group; the persistence of stomachache and abdominal distension in the experiment group were shorter than that in the contrast group(P < 0.05).  Conclusion  Jinlong capsule can decrease the incidence of partial adverse reaction after TACE, cut short the persisting time of adverse reaction, improves the quality of life after TACE, and reduces damage to organs caused by TACE. 
Keywords:Jinlong capsule  heptocellular carcinoma  transcatheter arterial chemoembolization  adverse reaction
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国肿瘤临床》浏览原始摘要信息
点击此处可从《中国肿瘤临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号